About this study
Gliomas are the most common brain tumors in children and teens. These tumors can act differently in each person. Some teens and young adults have gliomas with changes in genes called IDH1 or IDH2. Most low-grade gliomas do not have these changes, but small number of them do.
The PNOC017 study is important because current treatments do not always work well for glioma. Some tumors come back or they do not respond to treatment. The side effects can also be hard to manage.
PNOC017 tests 2 cancer drugs — pamiparib (BGB-290) and temozolomide (TMZ) — in people whose tumors have IDH gene changes. The goal is to see if using both drugs works better than using TMZ alone. TMZ is a chemotherapy often used to treat glioma.
BGB-290 is known as a PARP inhibitor. PARP’s job is to fix broken DNA in cells. When PARP is blocked (inhibited), cancer cells cannot repair themselves, which can cause them to die. BGB-290 is a type of targeted therapy. It may make tumor cells with IDH changes more sensitive to the effects of TMZ chemotherapy.
People in the study will get different doses of BGB-290 along with a standard dose of TMZ. The study team will watch closely for side effects. They will also track how the tumor responds, such as whether it shrinks, grows more slowly, or stays the same.
If this study works well, it could lead to better treatments and possibly fewer side effects for people with IDH-mutant gliomas.
Eligibility overview
- Age 13–39 years
- Newly diagnosed or recurrent high-grade glioma, or recurrent low-grade glioma
- Tumor has an IDH1 or IDH2 mutation
- Good organ function
- No other active cancers or serious health problems